Clinical trials: Seizures, Epileptic
Nonepileptic Seizures
Treating Non-epileptic Seizures Using Magnetic Brain Stimulation
The purpose of this study is to investigate the feasibility of using repetitive transcranial magnetic stimulation (rTMS) - a form of non-invasive brain stimulation - to decrease the frequency of psychogenic non-epileptic seizure…
- Trial name
- NCT02796924
- Testing
- MagStim Rapid2 Transcranial Magnetic Simulation
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Childhood or Juvenile Absence Epilepsy
Mutual Interactions Between Absence Epilepsy Seizures and the Integration of Sensory Stimuli
Epileptic seizures arise from neuronal defects that often alter the capacity of the brain to process sensory information. During absence seizures, a frequent epileptic syndrome in children, the normal conscious and perceptual…
- Trial name
- Absence SLI (NCT03676543)
- Testing
- Timed repetitive sensory stimulation
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neurologic Disorder, Seizure Disorder
Statistical Analysis of Prevalence, Incidence, Comorbidities and Medical Expense in Epileptic Children in Taiwan Based on National Health Research Insurance Database.
Epilepsy is a common disease in pediatric neurology. In recent years, due to the promotion of Taiwan's health insurance and the advancement of related medical treatments and anti-epileptic drugs, the prevalence, incidence, and…
- Trial name
- NCT06542952
- Testing
- seizure
- Where
- 2 sites in Taiwan
- Volunteers
- 169,026 people
- Sponsor
- National Taiwan University Hospital
Epilepsy
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization
This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).
- Trial name
- NCT02726074
- Testing
- Perampanel
- Where
- 6 sites in South Korea
- Volunteers
- 106 people
- Sponsor
- Eisai Korea Inc.
Epilepsy, Lennox Gastaut Syndrome
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
- Trial name
- GWPCARE3 (NCT02224560)
- Testing
- GWP42003-P
- Where
- 29 sites in United States, France and 2 more
- Volunteers
- 225 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Epilepsy, Seizures
A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome
The purpose of this study is to evaluate the effectiveness and safety of topiramate as add-on therapy in the treatment of epilepsy patients with Lennox-Gastaut syndrome, a severe form of epilepsy in which there are mixed types of…
- Trial name
- NCT00236756
- Testing
- topiramate
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Epilepsy in Children
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
- Conditions
- Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease
- Trial name
- EPIK (NCT04639310)
- Testing
- XEN496
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
This is an open Label study to investigate the safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients.
- Trial name
- NCT01422720
- Testing
- Eslicarbazepine Acetate
- Where
- 48 sites in Austria, Bulgaria and 8 more
- Volunteers
- 72 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Dissociative Seizures
Mainz Epilepsy Registry
Prospective longitudinal observational registry study of all patients with epilepsy treated in the Mainz Comprehensive Epilepsy and Sleep Medicine Center with the focus on the course of the disease and quality of life.
- Conditions
- Epilepsy, Dissociative Seizures, Status Epilepticus
- Trial name
- MAINZ-EPIREG (NCT05267405)
- Testing
- no interventions, only observation
- Where
- Germany
- Volunteers
- 700 people
- Sponsor
- Johannes Gutenberg University Mainz
Epilepsy, Seizures
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day [mg/day]) as an adjunctive therapy…
- Trial name
- NCT03754582
- Testing
- Perampanel
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Partial-Onset Seizures
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.
- Conditions
- Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT02736162
- Testing
- No treatment (intervention) was administered
- Volunteers
- 61 people
- Sponsor
- Eisai Inc.
Epilepsy, Seizures
BHV-7000 Responsive Neurostimulation System (RNS) Study
This is an open label study to assess the biological effect of BHV-7000 on abnormal activity recorded by the RNS System in patients with focal epilepsy implanted with the RNS System.
- Trial name
- NCT07125261
- Testing
- BHV-700
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Rolandic Epilepsy, Rolandic Epilepsy, Benign
Sleep Spindles and Memory in Rolandic Epilepsy
The investigators are recruiting children with Rolandic epilepsy and children without epilepsy (aged 4 years old and above) for a non-invasive brain imaging study using Magnetic Resonance Imaging (MRI)…
- Conditions
- Rolandic Epilepsy, Rolandic Epilepsy, Benign, Centrotemporal Epilepsy, Centrotemporal; EEG Spikes, Epilepsy of Childhood
- Trial name
- NCT04569708
- Testing
- Closed loop auditory stimulation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Post Stroke Epilepsy, Stroke
Predisposing Factors for Post-stroke Epilepsy
The goal of this observational study is to learn about epilepsy after a stroke (post-stroke epilepsy). The main questions it aims to answer are: What make some patients develop epilepsy after a stroke? Does sleep have an impact…
- Conditions
- Post Stroke Epilepsy, Stroke, Epilepsy, Seizures
- Trial name
- PRESTEP (NCT05864547)
- Where
- Norway
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Epilepsy Intractable
Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs
Epilepsy, a prevalent neurological disorder, affects 40% of patients with uncontrolled seizures despite medications. Sleep disturbance exacerbates epilepsy, and vice versa, but existing literature suffers from limitations.
- Trial name
- NCT06545643
- Testing
- Dreem headband
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Duke University
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Generalized Epilepsy
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
An open-label, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV), in children (≥ 4 years old), adolescents and adults suffering from primary generalized seizures.
- Trial name
- NCT00150748
- Testing
- Levetiracetam 166 mg, Levetiracetam 250 mg, Levetiracetam 500 mg
- Volunteers
- 217 people
- Sponsor
- UCB Pharma SA
Epilepsy
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin
- Trial name
- NCT00567424
- Testing
- GW273225
- Where
- 30 sites in United States
- Sponsor
- GlaxoSmithKline